<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515747</url>
  </required_header>
  <id_info>
    <org_study_id>01200406198</org_study_id>
    <nct_id>NCT02515747</nct_id>
  </id_info>
  <brief_title>Prospective Russian Evaluation of Lp(a) Role in cardiovascUlar DiseasE</brief_title>
  <acronym>PRELUDE</acronym>
  <official_title>Role of Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype in Prediction of Coronary Events in General Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Russian Cardiology Research and Production Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Russian Cardiology Research and Production Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the role of lipoprotein(a) and apolipoprotein(a)
      phenotype in fatal and non-fatal cardiovascular disease (CVD) events risk in coronary disease
      patients divided on the basis of management strategy - medical, endovascular or open cardiac
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between January 1993 and September 2006, we enrolled 1400 consecutive patients from the
      Atherosclerosis Department with known Lp(a) levels and coronary heart disease (CHD) verified
      by angiography. In accordance with clinical condition and angiography data were assigned them
      into three parallel treatment arms and followed up to 15 years. This study was conducted
      according to the principles of the Declaration of Helsinki and the Institutional Ethics
      Committee.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1993</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>non-fatal myocardial infarction and cardiovascular death</measure>
    <time_frame>up to 15 years</time_frame>
    <description>we took a composite primary outcome measure because anticipated a low number of hard-end-points in each treatment arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>non-fatal myocardial infarction and cardiovascular death and myocardial revascularisation and hospitalization for recurrent or unstable angina</measure>
    <time_frame>up to 15 years</time_frame>
    <description>we chose a composite secondary outcome mesure as a standard for such type studies and to obtain a statistical difference between the groups</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1400</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>conservative treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Men and women with stable CHD verified by angiography from one center and allocated to three treatment arms in real-world practice: 1. conservative treatment with statins, antiaggregants, antianginal drugs in standard dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>percutaneous coronary intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2. elective balloon angioplasty alone or stent implanation on the basement of drugs treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>coronary artery bypass grafting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>elective surgery myocardial revascularisation on the basement of drugs treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>percutaneous coronary intervention</intervention_name>
    <description>elective percutaneous coronary balloon angioplasty and/or stenting</description>
    <arm_group_label>percutaneous coronary intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>coronary artery bypass grafting</intervention_name>
    <description>elective surgical myocardial revascularisation</description>
    <arm_group_label>coronary artery bypass grafting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable coronary heart disease verified by angiography

        Exclusion Criteria:

          -  acute coronary syndromes,

          -  acute infections,

          -  inflammatory disease within 3 months prior to inclusion,

          -  familial hypercholesterolemia,

          -  triglycerides&gt;4.5 mmol/L,

          -  missing Lp(a) measurements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marat V. Ezhov, PhD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Russian Cardiology Research and Production Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergei N. Pokrovsky, PhD, DSc</last_name>
    <role>Study Chair</role>
    <affiliation>Russian Cardiology Research and Production Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valery V. Kukharchuk, PhD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Russian Cardiology Research and Production Center</affiliation>
  </overall_official>
  <reference>
    <citation>Ezhov MV, Afanas'eva OI, Kambegova AA, Afanas'eva MI, Trukhacheva EP, Naumov VG, Pokrovskiĭ SN. [The role of atherosclerosis risk factors in development of ischemic heart disease in young men]. Ter Arkh. 2009;81(5):50-4. Russian.</citation>
    <PMID>19537587</PMID>
  </reference>
  <reference>
    <citation>Ezhov MV, Liakishev AA, Pokrovskiĭ SN. [Lipoprotein (a) - an independent risk factor in atherosclerosis]. Ter Arkh. 2001;73(9):76-82. Review. Russian.</citation>
    <PMID>11642088</PMID>
  </reference>
  <results_reference>
    <citation>Pokrovsky SN, Ezhov MV, Il'ina LN, Afanasieva OI, Sinitsyn VY, Shiriaev AA, Akchurin RS. Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003 Oct;126(4):1071-5.</citation>
    <PMID>14566249</PMID>
  </results_reference>
  <results_reference>
    <citation>Ezhov MV, Safarova MC, Afanas'eva OI, Il'ina LN, Liakishev AA, Pokrovskiĭ SN. [High level of lipoprotein (a) as a predictor of poor long-term prognosis after coronary artery bypass surgery]. Kardiologiia. 2011;51(1):18-22. Russian.</citation>
    <PMID>21626797</PMID>
  </results_reference>
  <results_reference>
    <citation>Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis. 2014 Aug;235(2):477-82. doi: 10.1016/j.atherosclerosis.2014.05.944. Epub 2014 Jun 4.</citation>
    <PMID>24952151</PMID>
  </results_reference>
  <results_reference>
    <citation>Britareva VV, Afanas'eva OI, Dobrovol'skiĭ AB, Ezhov MV, Titaeva EV, Karpov IuA, Pokrovskiĭ SN. [Lipoprotein(a) and Apo-A isoforms in patients with intermittent claudication]. Ter Arkh. 2002;74(12):49-52. Russian.</citation>
    <PMID>12577841</PMID>
  </results_reference>
  <results_reference>
    <citation>Ezhov MV, Afanas'eva OI, Benevolenskaia GF, Savchenko AP, Balakhonova TV, Liakishev AA, Pokrovskiĭ SN. [Association of lipoprotein(a) and apolipoprotein(a) phenotypes with coronary and carotid atherosclerosis in CHD men]. Ter Arkh. 2000;72(1):28-32. Russian.</citation>
    <PMID>10687202</PMID>
  </results_reference>
  <results_reference>
    <citation>Ezhov MV, Afanas'ev OI, Benevolenskaia GF, Savchenko AP, Liakishev AA, Pokrovskiĭ SN. [Lipoprotein(a) as a biochemical marker of coronary atherosclerosis]. Ter Arkh. 1997;69(9):31-4. Russian.</citation>
    <PMID>9411822</PMID>
  </results_reference>
  <results_reference>
    <citation>Safarova MS, Trukhacheva EP, Ezhov MV, Afanas'eva OI, Afanas'eva MI, Tripoten' MI, Liakishev AA, Pokrovskiĭ SN. [Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels]. Kardiologiia. 2011;51(5):9-16. Russian.</citation>
    <PMID>21649590</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>August 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <last_update_submitted>August 1, 2015</last_update_submitted>
  <last_update_submitted_qc>August 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Russian Cardiology Research and Production Center</investigator_affiliation>
    <investigator_full_name>Marat Vladislavovich Ezhov (MV Ezhov, MD, PhD, DMSc)</investigator_full_name>
    <investigator_title>Associate Professor, Dr.</investigator_title>
  </responsible_party>
  <keyword>Lipoprotein(a)</keyword>
  <keyword>coronary artery bypass grafting (CABG)</keyword>
  <keyword>apo(a)</keyword>
  <keyword>prognosis</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>cardiovascular death</keyword>
  <keyword>percutaneous coronary intervention (PCI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

